Overview

• US pharmaceutical company's Q4 2025 product revenue reached $1.6 mln after VIZZ launch

• Net loss for Q4 2025 widened to $35.9 mln, reflecting higher SG&A expenses

• Company expanded sales force to support VIZZ demand and prescriber uptake

Outlook

• Company expects over 45,000 paid prescriptions for VIZZ from launch through Q1 2026

• LENZ is expanding sales force to 117 territories, full deployment expected in Q2 2026

• Company continues international regulatory filings and partnerships for VIZZ in Europe and Asia

Result Drivers

• PRESCRIBER ADOPTION - Broad uptake by eye care professionals drove initial VIZZ sales, with over 6,500 unique prescribers in Q4 2025 and over 20,000 prescriptions filled

• CONSUMER AWARENESS CAMPAIGN - Direct-to-consumer campaign featuring Sarah Jessica Parker increased consumer engagement and website traffic

• SALES FORCE EXPANSION - Company expanded sales organization to support growing demand and prescriber base

Company press release: ID:nGNXZhQvL

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$35.90 mln
Q4 Income from Operations		-$38.46 mln
Q4 Operating Expenses		$40.05 mln

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for LENZ Therapeutics Inc is $52.00, about 372.7% above its March 23 closing price of $11.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.